SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 7, 2006.

BioTime, Inc.

(Exact name of registrant as specified in its charter)

California	**1-12830**	**94-3127919**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6121 Hollis Street
Emeryville, California 94608
(Address of principal executive offices)

(510) 350-2940
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission. Words such as "expects," "may," "will," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions identify forward-looking statements.

Section 7 Regulation FD

Item 7.01 Regulation FD Disclosure

The press release filed as Exhibit 99.1 is incorporated by reference.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press release dated December 7, 2006

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOTIME, INC.

Date: December 7, 2006

By: /s/Judith Segall
Vice President - Operations
Member, Office of the President

Exhibit Number	Description
99.1	Press release dated December 7, 2006

Exhibit 99.1

BioTime, Inc.

6121 Hollis Street
Emeryville, CA 94608
Tel: 510-350-2940
Fax: 510-350-2948
www.biotimeinc.com

For Further Information:
Judith Segall (510) 350-2940

FOR IMMEDIATE RELEASE
December 7, 2006

BIOTIME ANNOUNCES A PHASE II CLINICAL TRIAL OF HEXTEND® IN JAPAN

EMERYVILLE, CA, December 7, 2006 - BioTime, Inc. (OTCBB: BTIM) announced today that a Phase II clinical trial for Hextend® is being conducted in Japan by Summit Pharmaceuticals International Corporation under their license agreement with BioTime. Summit is co-developing Hextend for the Japanese market with Maruishi Pharmaceutical Co., Ltd. and both Maruishi and Summit have the right to co-market Hextend if regulatory approval is obtained. Summit expects Phase III clinical studies to commence in 2008.

Hextend has been formulated to restore and maintain plasma volume longer than the plasma volume expanders currently marketed in Japan. Summit estimates that there are on average at least 1 million surgery cases per year in Japan that involve the use of plasma volume expanders.

Hextend is a physiologically balanced blood plasma volume expander, for the treatment of hypovolemia. Hextend is being distributed in the United States and Canada by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licenses from BioTime. Hospira also has the right to obtain regulatory approval and market Hextend in Latin America and Australia. Summit has a license to develop Hextend in Japan, the People's Republic of China, and Taiwan.

BioTime, headquartered in Emeryville, California develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Information about BioTime can be found on the web at www.biotimeinc.com.

The matters discussed in this press release include forward-looking statements which are subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated. Such risks and uncertainties include but are not limited to the results of clinical trials of Hextend®, the ability of Summit and Maruishi to obtain regulatory approval to market Hextend® in Japan; competition from products manufactured and sold or being developed by other companies; the price of and demand for Hextend®; and the availability of reimbursement for the cost of Hextend® and related treatment from government health administration authorities, private health coverage insurers and other organizations. These and other risk factors are discussed in BioTime's Annual Report on Form 10-K filed with the Securities and Exchange Commission.